Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 923-835-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 22 April 2008 - 22 june 2008
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- except during study days -6 to 9, and except for the absence of chemical analyses of dosage forms
- Limit test:
- no
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Details on test material:
- - Name of test material (as cited in study report): LCE07104 = Alkylpolyglucoside
- Substance type: UVCB
- Physical state: white powder
- Purity: not indicated
- Impurities (identity and concentrations): not indicated
- Percentage of components: not indicated
- Purity test date: not indicated
- Lot/batch No.: T71225
- Expiration date of the lot/batch: 21 March 2009
- Stability under test conditions: not indicated
- Storage condition of test material: at room temperature, protected from sunlight
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: breeder
- Age at first treatment: approx. 10 weeks
- Weight at first treatment (mean): M=433 g, F=276 g
- Housing: individually, except during pairing
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Relative humidity: 50 ± 20%
- Light/dark cycle: 12h/12h
- Ventilation: 12 cycles/hour of filtered, non-recycled air.
IN-LIFE DATES: beginning: 29 April 2008 / end: up to 21 June 2008
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
test item was ground, heated to 80°C, mixed with vehicle heated to 80°C, forming a suspension.
The test item dosage forms were prepared daily
VEHICLE
- Justification for use and choice of vehicle (if other than water): lipophilicity of the substance
- Concentration in vehicle: 10, 30 and 100 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg/day
- Lot/batch no. (if required): 057K6093, A0247283 and 1223873
- Purity: not indicated - Details on mating procedure:
- - M/F ratio per cage: 1
- Length of cohabitation: until mating occurred
- Proof of pregnancy: vaginal plug, or sperm in vaginal smear - referred to as day 0 post-coitum
- In case of unsuccessful pairing: not detailed (pairing always succeeded)
- After successful mating each pregnant female was caged individually - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Absence of a practical method of analysis
- Duration of treatment / exposure:
- from 2 weeks before mating until the end of mating (males: total of 39 days) or day 5 pp (females: total of 44-55 days)
- Frequency of treatment:
- once daily
- Details on study schedule:
- - no F1 parents (only one generation mated).
- Age at mating of the mated animals in the study: 13-16 weeks
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 100, 300, 1000 mg/kg/day (m/f)
Basis:
other: nominal per gavage
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: no serious effects at up to 1000 mg/kg/day in a 14-day range-finding study, see 7.5.1
- Rationale for animal assignment: computerized stratification procedure (average body weight of each group is similar) - Positive control:
- none
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice a day
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
BODY WEIGHT: Yes
- Time schedule: day 1 and then weekly; and in F also days 0, 7, 14 and 20 post-coitum and days 1 and 5 post-partum
FOOD CONSUMPTION for each animal: Yes
- Time schedule: weekly (last 7-day consumption period)
FOOD EFFICIENCY: No
WATER CONSUMPTION: No - Oestrous cyclicity (parental animals):
- Yes : from a fresh vaginal lavage, each morning during the mating period, until the females were mated
- Sperm parameters (parental animals):
- No seminology examinations.
Testis and epididymis : weight (all males), microscopic exmaination (some rats: see table 1). - Litter observations:
- STANDARDISATION OF LITTERS: No
PARAMETERS EXAMINED:
The following parameters were examined in offspring:
number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight on days 1 and 5, clinical signs - Postmortem examinations (parental animals):
- SACRIFICE
- All male survivors: after the end of the mating period
- All female survivors: on day 6 post-partum
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera.
HISTOPATHOLOGY / ORGAN WEIGHTS
The tissues indicated in Table 1 were prepared for microscopic examination and weighed, respectively. - Postmortem examinations (offspring):
- SACRIFICE
- Sacrifice on non-selected breeders/progeny: not applicable (only 1 generation of parents and of offspring)
- All pups sacrificed on day 5 post-partum
GROSS NECROPSY: Yes, on pups sacrificed and found dead
- external and internal examinations including the cervical, thoracic, and abdominal viscera.
HISTOPATHOLOGY / ORGAN WEIGTHS: Not performed - Reproductive indices:
- Pre-implantation loss = 100 * (Number of corpora lutea - Number of implantation sites) / Number of corpora lutea
Post-implantation loss = 100 * (Number of implantation sites - Number of live fetuses) / Number of implantation sites
Mating index = 100 * Number of mated animals / Number of paired animals
Fertility index = 100 * Number of pregnant female partners / Number of mated pairs
Gestation index = 100 * Number of females with live born pups / Number of pregnant females
Live birth index = 100 * Number of live born pups / Number of delivered pups - Offspring viability indices:
- Viability index = 100 * Number of surviving pups on day 5 post-partum / Number of live born pups
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Hypersalivation was observed in 11/20, 11/20, 16/20 and 13/20 animals treated at 0, 100, 300 or 1000 mg/kg/day, respectively (females counted during the pre-mating phase). Hypersalivation was observed mostly in or from the second week of dosing in the controls and low-dose group but was more often observed in week 1 in animals treated at 1000 mg/kg/day. During gestation slightly more females showed hypersalivation but it was observed in less females during lactation.
Reflux at dosing was observed in 0/20, 5/20, 3/20 and 7/20 animals treated at 0, 100, 300 or 1000 mg/kg/day, respectively. It was observed on one to five occasions in each affected animal and tended to occur towards the end of the dosing period.
Hypersalivation and reflux at dosing are considered to be related to treatment either with the vehicle and/or the test item but are non-adverse. - Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The male groups treated at 100 or 1000 mg/kg/day gained minimally less weight than the controls during treatment period as a whole (-11% and -8%, respectively), however the scale of the difference and the absence of a dose-relationship renders the effect not toxicologically significant.
No effects were observed on body weight evolution in males treated at 300 mg/kg/day.
There were no effects on mean female body weight or body weight gains during the pre-mating, gestation or lactation phase; all values were comparable with the controls. - Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Mean male food consumption at 1000 mg/kg/day was slightly lower than that of the controls
during the first week of treatment. This was in part due to male R21433 which consumed
markedly less than the other males in the group. During the second week of dosing the mean food
consumption was identical to the controls so it was considered that the slightly decrease in week 1
was not related to treatment with the test item. There were no effects on mean male food
consumption at 100 or 300 mg/kg/day.
Mean food consumption of all female groups treated with LCE07104 was apparently slightly lower than that of the controls during the second week of treatment, however one control female had a particularly high consumption which skewed the group mean. It was considered that there were no effects of treatment with the test item. There were no differences between the controls and the test item-treated groups during gestation and lactation. - Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Bile acid concentrations are highly variable and the differences in males and females were inconsistent.
Inorganic phosphorus concentration was unaffected in males and slightly increased in females treated at 1000 mg/kg/day.
It was considered that neither of these parameters had been affected by treatment with the test item. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
Details on results (P0)
Effect levels (P0)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- parental toxicity
- Effect level:
- ca. 1 000 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- clinical signs
- mortality
- body weight and weight gain
- food consumption and compound intake
- haematology
- clinical biochemistry
- organ weights and organ / body weight ratios
- gross pathology
- histopathology: non-neoplastic
- histopathology: neoplastic
- other: NOAEL = highest tested dose, without relevant effects.
- Key result
- Dose descriptor:
- NOEL
- Remarks:
- reproduction (mating and fertility)
- Effect level:
- ca. 1 000 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- reproductive function (oestrous cycle)
- reproductive performance
- other: NOEL = highest tested dose, without relevant effects.
Results: P1 (second parental generation)
General toxicity (P1)
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- not examined
- Body weight and weight changes:
- not examined
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
Reproductive function / performance (P1)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- not examined
Details on results (P1)
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Isolated clinical signs were observed in a few animals per group, except the group treated at 1000 mg/kg/day whose pups showed no clinical signs, but no one sign was observed consistently.
It was considered that there were no effects of treatment with the test item. - Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- Pup survival was not markedly different between the control group and the groups treated with LCE07104
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The mean body weight gain of the pups from the group treated at 100 or 1000 mg/kg/day was
slightly lower than that of the controls from day 1 to day 5 post-partum, however individual litter
values were within the control range. It was therefore considered that the apparent effect was not
related to treatment with the test item. - Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Details on results (F1)
Effect levels (F1)
- Key result
- Dose descriptor:
- NOEL
- Remarks:
- offspring toxicity
- Generation:
- F1
- Effect level:
- ca. 1 000 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- viability
- clinical signs
- mortality
- body weight and weight gain
- gross pathology
- other: NOEL = highest tested dose, without relevant effects.
Results: F2 generation
General toxicity (F2)
- Clinical signs:
- not examined
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- not examined
- Body weight and weight changes:
- not examined
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Histopathological findings:
- not examined
- Other effects:
- not examined
Developmental neurotoxicity (F2)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F2)
- Developmental immunotoxicity:
- not examined
Details on results (F2)
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
Not required (no effects)
Applicant's summary and conclusion
- Conclusions:
- Under on the experimental conditions of this study, the No Observed Adverse Effect Level (NOAEL) for parental toxicity was considered to be 1000 mg/kg/day, the No Observed Effect Level (NOEL) for reproductive performance (mating and fertility) was considered to be 1000 mg/kg/day and the NOEL for toxic effects on progeny was 1000 mg/kg/day.
Considering REACH Annex IX 8.7.2 and 8.7.3 criteria alone, a developmental toxicity study and a two-generation study in one species should be proposed as the substance is not genotoxic or toxic to reproduction according to available data, and there are no data on plasmatic exposure after dosing. However, although no exemption can be derived from these criteria, it should be underlined that it seems irrelevant to propose and perform this test, both from scientific and regulatory standpoints:
- the substance is clearly non-toxic based on the available tests including evaluations of fertility and development (as detailed above),
- it is expected to be metabolised into endogenous compounds (as discussed under 5.1),
- the expected metabolism and excretion do not suggest any bioaccumulation potential (as discussed under 5.1),
- exposure of workers is negligible when taking into account the high particle size limiting dermal and respiratory absorption (as discussed under 5.1), and the various risk management measures which are applied by SEPPIC (summarized under part A.1),
- the risk assessment for consumers of the final cosmetic product is exempted under REACH, Directive 2003/15/EC forbids in vivo testing on cosmetic ingredients for the dossier of the final cosmetic product from March 2009, and cosmetic regulations are stated to prevail over REACH requirements. - Executive summary:
The test item, LCE07104, was administered daily by oral gavage to male and female Sprague-Dawley rats, for 2 weeks before mating, during mating, gestation and until day 5 post-partum, at dose-levels of 100, 300 or 1000 mg/kg/day.
There were no unscheduled deaths during the study and the only clinical signs observed were hypersalivation and reflux at dosing, which were considered to be related to treatment with the test item but were non-adverse. There were no treatment-related effects on body weight, body weight gain or food consumption at any dose-level. There were no differences from controls for pairing, mating and fertility parameters. Pups showed no effects of treatment on survival or body weight performance.
There were no treatment-related effects on organ weights and no treatment-related macroscopic or microscopic findings were observed.
Considering REACH Annex IX 8.7.2 and 8.7.3 criteria alone, a developmental toxicity study and a two-generation study in one species should be proposed as the substance is not genotoxic or toxic to reproduction according to available data, and there are no data on plasmatic exposure after dosing. However, although no exemption can be derived from these criteria, it should be underlined that it seems irrelevant to propose and perform this test, both from scientific and regulatory standpoints:
- the substance is clearly non-toxic based on the available tests including evaluations of fertility and development (as detailed above),
- it is expected to be metabolised into endogenous compounds (as discussed under 5.1),
- the expected metabolism and excretion do not suggest any bioaccumulation potential (as discussed under 5.1),
- exposure of workers is negligible when taking into account the high particle size limiting dermal and respiratory absorption (as discussed under 5.1), and the various risk management measures which are applied by SEPPIC (summarized under part A.1),
the risk assessment for consumers of the final cosmetic product is exempted under REACH, Directive 2003/15/EC forbids in vivo testing on cosmetic ingredients for the dossier of the final cosmetic product from March 2009, and cosmetic regulations are stated to prevail over REACH requirements.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
